ReviewNeuroRx : the journal of the American Society for Experimental NeuroTherapeutics2004
Cell therapy in Huntington's disease.
Review in NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 74 citations in OpenAlex.
- Advancements in surgical treatments for Huntington disease: From pallidotomy to experimental therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Review
- SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington's disease.NPJ Regenerative medicine · 2022Article
- Transplantation of human embryonic stem cells alleviates motor dysfunction in AAV2-Htt171-82Q transfected rat model of Huntington's disease.Stem cell research & therapy · 2021Article
- Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease.Stem cells (Dayton, Ohio) · 2020Article
- Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?Frontiers in cellular neuroscience · 2020Review
- Can manipulation of differentiation conditions eliminate proliferative cells from a population of ES cell-derived forebrain cells?Neurogenesis (Austin, Tex.) · 2016Article
- Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.Cell stem cell · 2012Article
- Antioxidants in Huntington's disease.Biochimica et biophysica acta · 2012Review
- Experimental surgical therapies for Huntington's disease.CNS neuroscience & therapeutics · 2011Review
- Differential fate and functional outcome of lithium chloride primed adult neural progenitor cell transplants in a rat model of Huntington disease.Stem cell research & therapy · 2010Article
- BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease.Gene therapy · 2010Article
- Stem Cells Transplantation and Huntington's Disease.International journal of stem cells · 2009Review
- Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease.Journal of neuroscience research · 2009Article
- Composite MR Contrast Agents for Conditional Cell-Labeling.International journal of imaging systems and technology · 2008Article
- Nonviral approaches for neuronal delivery of nucleic acids.Pharmaceutical research · 2008Review
- Neurodegeneration and cell replacement.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2008Review
- Therapeutic Strategies in Huntington's Disease.Journal of clinical neurology (Seoul, Korea) · 2006Article
- Update on Huntington's disease.Current neurology and neuroscience reports · 2006Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease is an autosomal dominant genetic disease, which results in progressive neuronal degeneration in the neostriatum and neocortex, and associated functional impairments in motor, cognitive, and psychiatric domains. Although the genetic mutation is identified, involving an abnormal CAG expansion within the htt gene on chromosome 4, the mechanism by which this leads to neuronal cell death and the question of why striatal neurones are targeted both remain unknown. Thus, in addition to the search for molecular and genetic strategies to inhibit development of the disease, we still need to identify effective strategies for cellular repair in affected individuals. Aspects of the human neuropathology can be well modeled by excitotoxic or metabolic lesions in experimental animals, and in transgenic mice carrying the htt mutation, providing the basis for testing alternative therapeutic strategies. The rationale and efficacy of alternative cell therapies are reviewed, including transplantation repair with embryonic striatal tissues, expansion and differentiation of striatal-like cells from stem cells, and in vivo and ex vivo gene therapy for delivery of neuroprotective growth factor molecules. Pilot and experimental clinical trials of several approaches are now also underway, and the alternative strategies are compared.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.